MacroGenics insider exercises 8,000 options for MacroGenics stock

Published on 10/08/2026 at 14:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MacroGenics stock costs EUR 3.16 on October 8, 2026 after EUR 3.17, minus 0.32 percent. Second-quarter revenue reached USD 32.80 million.

MGNX, US5560991094, Illustration mit AI erstellt.

MacroGenics (US5560991094) had senior executive Ezio Bonvini exercise 8,000 options on October 6, 2026 at USD 2.60 per share, according to StockTitan. The stock was at EUR 3.16 at Lang & Schwarz on October 8, 2026 at 2:05 p.m. CEST, minus 0.32 percent versus the prior close of EUR 3.17.

Three dated pipeline milestones

MarketScreener lists an August 11, 2026 milestone tied to Gilead Sciences' exercise of an option, worth USD 10.00 million to MacroGenics. On September 9, 2026, MacroGenics announced a presentation at the H.C. Wainwright conference scheduled for September 16 at 9:30 a.m. ET. The latest dated event was the October 6 option exercise involving 8,000 shares at USD 2.60.

What does the second quarter show?

According to Simply Wall St, second-quarter 2026 revenue reached USD 32.80 million, up 378.00 percent from the year-earlier period. The same report put the net loss at USD 69.60 million, compared with a USD 36.80 million loss in the first quarter of 2026. That contrast leaves the revenue increase dependent on the company's pipeline and licensing activity rather than current profitability.

MacroGenics describes itself as a clinical-stage biotechnology company developing antibody-drug conjugates, bispecific checkpoint antibodies and T-cell engagers. Its investor materials identify collaborations with Incyte, Gilead and Sanofi, giving partnership milestones a direct role in the financial profile.

Upcoming dates carry the next figures

The next disclosed clinical milestone is the European Society for Medical Oncology meeting from October 23 through October 27, 2026, where data for MGC026 and lorigerlimab are expected, according to Simply Wall St. The next earnings date listed by The Desperate Trader is November 11, 2026.

Stock remains below its yearly high

MacroGenics had a market capitalization of USD 225.6 million on October 8, 2026. Its 52-week range was USD 1.29 to USD 5.08 on October 7, 2026, placing the EUR 3.16 Lang & Schwarz quote in a volatile small-cap biotechnology setting. The company reported cash of USD 113.9 million at June 30, 2026, while operating cash flow for the second quarter was negative USD 40.7 million. The further course of trading is shown by the continuously updated real-time quote of MacroGenics stock.